RESEARCH TRIANGLE PARK, N.C., December 18, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug ...

RADNOR, Pa. - Certara, Inc. (NASDAQ:CERT), a company specializing in model-informed drug development, today announced the launch of its Non-Animal Navigator™, a tool aimed at assisting ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ...

Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP’s services help across discovery, development, and clinical ...

The complexities of drug development for rare diseases, including small patient populations, phenotypic variability, and the high costs associated with large-scale clinical trials, have long hindered ...

Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth ...

Certara ( (CERT)) has provided an update. On December 11, 2025, Certara, a leader in model-informed drug development, announced the appointment of Jon Resnick as the new Chief Executive Officer, ...